Loading…
Reported covered position: Staff Assist., Rep. Frank Pallone (2003-04)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · third_quarter · Q3
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
Source: Senate LDA
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; H.R.5, Help Efficient Accessible Low-Cost Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Drug Price Competition Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Drug Price Competition Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Drug Price Competition Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Drug Price Competition Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Independent Drug Education and Outreach Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Trans-Pacific Partnership Trade Agreement
S.27, Preserve Access to Affordable Generics Act; and S.1882, Fair & Immediate Release of Generic Drug Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · second_quarter · Q2
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
Trans-Pacific Partnership Trade Agreement
S.27, Preserve Access to Affordable Generics Act; and S.1882, Fair & Immediate Release of Generic Drug Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · first_quarter · Q1
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; H.R.5, Help Efficient Accessible Low-Cost Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · fourth_quarter · Q4
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals; S. 1357, Affordable Medicines Utilization Act of 2011.
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · third_quarter · Q3
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.
U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals; S. 1357, Affordable Medicines Utilization Act of 2011.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · second_quarter · Q2
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals.
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · first_quarter · Q1
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011.
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · fourth_quarter · Q4
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals and "paired port" issue.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · third_quarter · 3A
Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals and "paired port" issue.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · third_quarter · 3A
Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals and "paired port" issue.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · third_quarter · Q3
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals and "paired port" issue.
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)